An Open-label Study to Characterize Safety and Tolerability of Repatha in Homozygous Familial Hypercholesterolemia in India

Registry ID

EUCTR2020-005111-51

Source registry

EUCTR

Phase

PHASE4

Sponsor

Amgen Inc.

Last update

2026-08-16

Conditions

• Homozygous Familial Hypercholesterolemia (HoFH)

Summary

To characterize the safety and tolerability in homozygous familial hypercholesterolemia HoFH patients in India exposed to 12 weeks of Repatha.

Related clinical trials

• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
• Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
• A Dose-exploration Study of EDP167 in HoFH
• Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
• The ORIGIN-FH Study

View on source registry